Monday, April 15, 2024
Johns Hopkins University
Baltimore, Maryland
The Long-Acting Extended Release Antiretroviral Research Resource Program (LEAP) virtually convened clinicians, investigators, developers, community advocacy groups, not-for-profit institutions and regulatory authorities. Attendees shared their diverse perspectives and discussed updates, challenges and future directions in the development of LA formulations. The meeting served as a forum to collectively advance the long-acting field.
Welcome: Conference Chairs, Eric Nuermberger & Kim Scarsi
[Presentation]
Welcome: Charles Flexner, Johns Hopkins University
[Presentation]
Welcome: Peter Kim, Director of Therapeutics Research Program , DAIDS/ NIAID
[Presentation]
Welcome: Jonathan Golub, Johns Hopkins University
[Presentation]
Welcome: Amita Gupta, Johns Hopkins University
[Presentation]
PLENARY SESSION 1 – Unmet Need and Principles
Roger Ptak, NIAID
NIAID Perspective on LA Drugs for TB
[Presentation]
Charles Wells, Gates MRI
GMRI Perspective on LA Drugs for TB
[Presentation]
Elisa Ignatius (Presented by Eric Nuermberger), Johns Hopkins University
Role of LA Drugs: Where Are We Now, Where Would We Like to Be?
[Presentation]
Andrew Owen, University of Liverpool
Progress & Challenges in Development of Long-Acting Medicines for TB Treatment & Prevention
[Presentation]
Charles Peloquin, University of Florida
PK-PD Drug Principles of TB Agents
[Presentation]
PLENARY SESSION 2 – Tools, Platforms, Progress
Eugene Sun and Rajneesh Taneja, TB Alliance
TB Alliance Perspective on Long-Acting TB Drugs, Including Diarylquinolines
[Presentation]
Vivian Cox, J&J
Long-Acting Bedaquiline
[Presentation]
J. Victor Garcia, University of Alabama Birmingham\
Long-Acting Rifabutin
[Presentation]
Eric Nuermberger, Johns Hopkins University
Long-Acting Rifapentine
[Presentation]
Kevin McHugh, Rice University
Leveraging Dynamic Covalent Bonding to Create a Long-Acting GSK656 Formulation: Pharmacokinetics and Efficacy Against TB
[Presentation]
PLENARY SESSION 3 – Path to a Commercial Product
Ramya Gopinath, FDA
Developing TB Drugs: A Regulatory Perspective
[Presentation]
Lindsay McKenna, TAG
Perspective from the Community and Advocates
[Presentation]
Paul Domanico, CHAI
Perspective from Clinton Health Access Initiative
[Presentation]